Luoxin Pharmaceuticals Group (002793) Fair Value & Analysis

Healthcare · CN · Market cap 4.4B CNY

Analysis

Luoxin Pharmaceuticals Group (002793) currently trades at ¥3.97, while our model-based Fair Value estimate is ¥2.26 — implying the stock looks roughly 43.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers health care services. Luoxin Pharmaceuticals Group Stock Co., Ltd. was formerly known as Zhejiang Doyin Pump Industry Co., Ltd. and changed its name to Luoxin Pharmaceuticals Group Stock Co., Ltd. in April 2020. The company was founded in 1998 and is based in Linyi, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.